Amgen Inc.

Tularik Limited

Oric Pharmaceuticals, Inc.

Amgen Sf, LLC

Other

Tenaya Therapeutics, Inc.

Epiodyne, Inc.

Chemocentryx, Inc.

Reiley Pharmaceuticals, Inc.

Julio Cesar Medina

Jonathan B Houze

Xiaohui Du

Jiwen Liu

Zice Fu

Zhihua Ma

Liusheng Zhu

Lawrence R McGee

Xiaoqi Chen

Jeffrey Thomas Mihalic

Jeffrey Deignan

Yingcai Wang

Paul John Dransfield

Xiaodong Wang

Steven H Olson

Vatee Pattaropong

David John Kopecky

Richard V Connors

Julie Anne Heath

Frank Kayser

Xuelei Yan

Michael G Johnson

Yosup Rew

Daqing Sun

Jason A Duquette

An-Rong Li

David Louis Clark

Ning Chen

Bei Shan

Su-Jen Lai

Michael J Schmitt

Kevin Chao Yang

Matthew R Kaller

Nobuko Nishimura

Daniel B Horne

Alan C Cheng

John Eksterowicz

John A Flygare

Terry J Rosen

Mikkel V Debenedetto

Gayathri Swaminath

Wang Shen

Ming Yu

Ted Charles Judd

Rajiv Sharma

Sean P Brown

Darin J Gustin

Jinqian Liu

Hilary Plake Beck

Wen-Chen Yeh

Ana Zurisadai Gonzalez Buenrostro

Yinhong Chen

Aarif Yusuf Khakoo

Marc Vimolratana

Felix Gonzalez Lopez De Turiso

Valeria R Fantin

Alan X Huang

Todd J Kohn

Brian M Fox

Michael D Bartberger

Zhihong Li

Pingyu Ding

Thomas T Nguyen

Snahel Patel

Leping Li

Jian Luo

Feng Xu

Joel McIntosh

Zhongyu Wang

Mike Elias Lizarzaburu

Melissa S Egbertson

John S Wai

Matthew Irvine Brown

Juan Carlos Jaen

Steven D Young

Dustin L McMinn

Jonathan Dante Low

Brian Stuart Lucas

Lars V Heumann

James P Guare

Jian Zhang

Michael R Degraffenreid

James S Harvey

Mark A Reiley

Joseph P Vacca

Harold G Selnick

Linghang Zhuang

Thomas J Schall

Alan Martin Allgeier

Daniel J Dairaghi

Joseph F Payack

Xianghong Wang

William Dvorak Shrader

Mario G Cardozo

Mark W Embrey

Sarah Lively

Kexue Li

Linda S Payne

Thorsten E Fisher

Brian E McMaster

Provided herein are compounds identified as inhibitors of HDAC6 activity having the formula: or a pharmaceutically acceptable salt thereof, that can be used to treat various diseases and disorders.

Fluoroalkyl-oxadiazoles and uses thereof

Provided herein are opioid receptor modulators and pharmaceutical compositions comprising said compounds.

Opioid receptor modulators

The present invention provides MDM2 inhibitor compounds of Formula I, or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer

Compounds are provided having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein A, B, L, R, R, R, R, R, m and n are as defined herein. Such compounds modulate the opioid receptor, particulare the mu-opioid receptor (MOR) and/or the kappa-opioid receptor (KOR), and/or the delta-opioid receptor (DOR). Products containing such compounds, as well as methods for their use and preparation, are also provided.

Opioid receptor modulators and products and methods related thereto

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Compounds that inhibit MCL-1 protein

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer. 

Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists

The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer and hypercortisolism.

Inhibitors of glucocorticoid receptor

Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Heteroaryl-substituted triazoles as APJ receptor agonists

The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.

Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula (I) and Formula (II) have the following structures: (I); (II). Intermediates (V) are also claimed. 

Triazole furan compounds as agonists of the APJ receptor

Growing community of inventors

San Carlos, CA, United States of America

Julio Cesar Medina